and Today, provide Medicare I'll thank then you and and for questions. the our open for discuss developments quarter call details third and on business corporate recent will financials, we progress the Thanks, us. joining Fuad reimbursement afternoon. Trip, will Good all
our coverage expect the policy the business. released administration in with minimally are week, all to I similar to glaucoma MAC MACs X-K potential XXXX. of or XX, was start first the surgery its to and coverage the related December was changing Last that LCD, topic contractor XX, Medicare invasive WPS, Medicare effective or procedures. learning X our a about. the recent impacts LCDs, and more most as expected, That's become will On interested October subject other people issue I'll an MIGS
While was focus coverage the their device or they criteria CPC, continuous-wave changed procedures. clear X which and for cyclophotocoagulation of basis the the LCDs MIGS is IRIDEX' also MicroPulse glaucoma for use,
incisional done with coincident cataract surgery. to nor surgical MIGS procedures are incisional While predominantly done they neither IRIDEX devices coincident commonly are procedures a are the done CPC surgery, cataract to
While believed and the context the driven in multiple changes, billing multiple codes motive and increase explanation cost it's rapid MACs procedure in expense they coverage cataract during per devices increase deployed a surgeons This intervention. were MIGS and reimbursement procedures one or provided in an drove rise by volume their total. for of large MIGS reacting to in in particularly little submitting
a cataract The labeled device call Medicare rigorous effectiveness device. canaloplasty work a newer means they on until performed that investigational, with several and clinical to out made devices single limit as concomitant both which were ineligible specifically goniotomy published. were and procedures procedures be MIGS is more with for enable and MIGS LCDs other to a procedure surgery These a single reimbursement
CPC continuing investigational. labeled received payment is Unlike MIGS as The coverage. LCDs confirm procedures, not the targeted that cyclophotocoagulation
on to for procedures characteristics list effectively performed criteria via CPC coverage patients limit reimbursement symptoms very patient an and the advanced-stage glaucoma. However, from suffering that redefined would extensive was of
procedures For continuous-wave stricter and fewer CPC our MACs, business, means patients for on procedures. enrolled these this restricted-coverage TLT in limitations MicroPulse
a high glaucoma the through procedures? LCDs IRIDEX' might following revenue. of sense there's situation. uncertainty. a of represent believe impact what fewer many So how have degree me still numbers We get assumptions on the run classifications the Let And the to and note,
key First, IRIDEX' cyclophotocoagulation international MAC states like Texas including be coverage. just payers CPC MACs of X The To restrictions, unaffected. cover MACs. about all covered Pennsylvania. clear, And in and of X have still these revenue in total footprint, the coverage of procedure the X/X in a the U.S. X Florida, X Further, and not the glaucoma is subject is to now the our to issued MACs. half change of its is United narrowing States
of XX approximately that glaucoma Medicare. estimates Society covered Glaucoma American XX% are patients U.S. -- the So sorry, by
our to of Our we Medicare estimate coverage. on moderate so probably volume performed older, bit little procedures severity, has are about advanced a XX% skews
MIGS by network within about covered which coverage UnitedHealthcare. are and are and administered of for coverage Aetna Advantage the like programs, MAC half Medicare updates their their are altered none for However, Medicare CPC traditional of Currently, of half criteria. or Advantage insurance Medicare, -- MACs' new patients by in issued as payers companies payers they've Advantage have these even
these procedures with being cannot impact coverage on under most the severe for for the time, most business. its least procedures the our or directly glaucoma about implies glaucoma fall coverage LCD and have of those moderate affected. IRIDEX this XX% will MAC predict U.S. At math U.S. more accurately patients system stage probe the affected changes The restrictions,
recently essential heard patients. to to patients. effective for during We've their uncertain and reductions At is offer react and of the a San particularly an not in for American how of coverage decisions physicians of treatment doctors, will our their Francisco, many it's the controlling but Ophthalmology glaucoma held treatment CPC only that part Academy proven this program to their time, progression
strong intention whom physicians coverage next for if for obviously is their treatment an option discussed under patients available plan. These self-pay CPC offering doctors their of the to the several possibility best And isn't CPC. continue performing communicated
important Qualitatively, there are considerations. X competing
and affected is the these surrounding states. frustration First to confusion changes reimbursement going physician MAC be in
in as providers restrictions how what and adoption, work probes they procedures our regions, affected CPC many aware non-reimbursed In and and our and leading through an affected of back around in MAC generally changed the not who's to be prospects pull the for expect position of coverage orders avoid offer will to confusion their individual can We domestic procedures. and may practice. will usage coverage consoles potential fewer to result patient's doctors has they deferring whom
alternatives. some And disease. going hand, a options the for deal On in receiving there IRIDEX. right in positives a MIGS other the are potential are with the treating attention. community wrestling big are LCDs and physicians lot the now, Ironically, of their this falling forward certainly includes glaucoma opportunity a existing plays LCDs interest marketing is and the IRIDEX' the thereby be greater that and into hardest procedures performed, should This right non-incisional in of glaucoma. there recognition MIGS MIGS reducing with positioning be number that need, will on almost in
effect number effort reduce of LCDs' ultimately The the for both significantly to MIGS improving opportunity CPC trigger market the in the OUS. offerings, the procedures longer-term our may U.S. of and
uptake more opportunity Ophthalmologists caught will restrictions, the as may champion growing that non-incisional and position to to a assortment of best have and LCD be working the MIGS physicians in for up coverage have alternative. the medicine. IRIDEX' And beyond open IRIDEX itself the been long pursuing to appeal patients,
more advanced It's a that basic commented patients disease to complicated as Many defer mistake higher-risk more feasible. toward us channel to as procedures early. surgeries late surgical to it's too clinicians management have
glaucoma the it of not many XXs, patients for result be includes XXs, there younger, and whom top healthy a in lifestyle-limiting involved and This complication-prone of XXs indicated. surgery individuals may in where candidates that, expensive otherwise older, and and may surgery On decades their are and also can be more poorer-health follow-up.
phase we're explaining LCDs, physicians, gaining and our own to with of have restricting strong appeal a of is We the and We've influential case believe within studies support of the specifics CPC a overly community. the some we working first mistake. the why reference their and whom several plan appeal, physician letters submitted gathering
set assessment years some conclusions of recommendations The an ultimately the by for qualifications. final erred CPC only by We patient in coverage, choosing They the erred narrow XX and they partially others. LCDs setting report resulting characteristics compounding believe by technology ignoring from for that from also patient AAO assessment old. criteria criteria overly that adopting is
LCDs with by assessment types list presented and AAO of resulting several to all must means between have the effect characteristics as qualify, patient CPC patient wrong. the that replaced symptoms each the The but listed The characteristics a patient them word clearly which and. this of commas type. is of The of options. a of quoted conclusion indicated the appropriate treatment that for appears list This
should, noting should, for emphasis LCDs process We on speedy correction believe and of word errors sent appeal correction the successive restriction the We definition. and the this to the a a CPC. lessen compelling of is to the coverage relatively adjustment to lead request rapid seeking
be may administrator will uncorrected, in MAC loss error We patients believe unrecoverable correct restriction. to the who date. the in this the if urge access of current We error erroneous of embodied promptly interpretation effective to because of vision lead wording, denied before the each
reconsideration preparing a criteria subsequent further for reimbursement. the also We're for appeal broaden to
surgeries, coverage trabeculectomy into like shunts. invasive a the account or not pushing appear tube undergone rate by surgeries must to did earlier First, requiring patient tools lead patient into safety life options invasive, it take more greater if follow-up IOP change higher-complication By patients have be too life. will you management is early, later required, in more later to up vision loss can control of greater your use limited. Basically,
study the evidence for was considering Second, flawed. process
submitted evidence efficacy our procedures treating types range of This and rejected process a body consider of broad have to summer, body of cyclophotocoagulation. seek we and over We Instead, most severities. patient papers them published this of that to the the appears XX MACs patients. on evidence. criteria studies X,XXX cyclophotocoagulation, large the supports safety to past support peer-reviewed clinical over in will of their It broader we a transscleral
our So this straight into leads programs. clinical ongoing updating
are patient will of of as clinical delay new decision producing road stated clinical consideration. will launch planned LCDs study our investigators. we to have key method This prospective potentially modest fortunate cause as end assess by new in the multicenter whether along and future criteria in well best be our data include the to within the protocol But discussed release aligned. As enroll we the for required prior, we're they that we've toward first already the the the as nonetheless opinion a reimbursement year had leaders
to time, physicians advance position on Having favorable. created and specifically We'll glaucoma at clinical of we're finalizing by very by the attention preparation in seems try patients, market study of and the CPC, same capitalizing targeted message the post-MIGS opportunity our to for rally efficacy support CPC LCDs. on IRIDEX
clinician efficacy a confidence increased prevail, will afforded. process the exposure and and positive at this have our and we relations have safety scale of procedures could never the awareness generated public through We provide can
company the Directors be This may whole. available strategic that explore Let a for to review and each an our the a me to appropriate lines time alternatives is recent is for shareholder of and of engaged product in of that as IRIDEX the to announcements value. to Board shift unlock options of future evaluation company
base business retina position has sales installed treatment specialists. achieved retina Our both for leadership a in systems laser ophthalmic in global and
Over the in the has past XX products the years, has and clinical set the and space. technical standards developed company
MicroPulse delivered to Therapy worldwide probes. Since over we've laser with MicroPulse patients G-Probe recently, Transscleral to with MP-TLT, platform launched and XX leading the over laser capability. advanced-stage with beginning transscleral market glaucoma recently ago launching more PASCAL cyclophotocoagulation and In treatment our of expanded we for patients. treatment single-use X,XXX Most the non-incisional we new moderate- for glaucoma, glaucoma presence XXX,XXX steadily the glaucoma provider years been Laser later-stage consoles
but been. commentary We're process disclosure our along Directors to Both and ever Board the through progressing offerings until of revenue the they've updates not way provide is our product that determines strongest appropriate. or do the plan
over The I perspective. items review Fuad of to financials, for sequentially, third is I'd quarter couple which the quarter positive Before softer to a like than given second a quarter. was QX generally line seasonally in of the add of turn is
of the quarter against This from the loss especially given XXXX was comparison year-over-year expirations. quarter tougher strong third
forward. back We saw primarily fortunately, our short-term that levels strategic the of about and But was expected might our announcement held concerned of orders inventory a going domestically, results. have carry distributors it impacted appropriate to little we review this of
on to the of we business the glaucoma of have high we cash guidance changes. the business our focused We and a may As runway reimbursement XXXX. impact reimbursement changes, variability as due to very to remain adjust the our operations suspended Medicare remain result operating and how intend unfold our to situation our from evaluate and glaucoma management these QX in U.S. our going into
financial that, to to With call Fuad quarter's I'll pass over results. the the discuss
